Alemtuzumab is a monoclonal antibody against the CD52 antigen present at high levels on
the surface of lymphocytes. While treatment of multiple sclerosis patients with alemtuzumab
results in marked depletion of lymphocytes from the circulation, it has not been associated
with a high incidence of serious infections. In a human CD52 transgenic mouse,
alemtuzumab treatment showed minimal impact on the number and function of innate
immune cells. A transient decrease in primary adaptive immune responses was observed …